Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions[1].
Purity:
98.67
CAS Number:
[2765066-99-5]
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
